Novartis News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

07.06.19	Novartis announces new leader of Pharmaceuticals Business Unit (GlobeNewswire)
06.06.19	Novartis presents first-of-its-kind histology data with iscalimab (CFZ533) suggesting the extended survival of transplanted organs may be possible (GlobeNewswire)
04.06.19	Long-term survival benefit shown for metastatic melanoma patients treated with Novartis Tafinlar® + Mekinist® (GlobeNewswire)
03.06.19	Novartis Shows Growing Strength in Lung Cancer Innovation with New Capmatinib Investigational Data and Novel Canakinumab Clinical Trials (GlobeNewswire)
03.06.19	Xolair® (omalizumab) significantly reduced nasal polyps and congestion symptoms in adults with chronic rhinosinusitis with nasal polyps in two phase III studies (GlobeNewswire)
01.06.19	Novartis Kisqali significantly extends life in women with HR+/HER2- advanced breast cancer in MONALEESA-7 trial (GlobeNewswire)
30.05.19	Novartis' phase III QUARTZ study of new investigational inhaled combination treatment QMF149 meets primary and key secondary endpoints in patients with inadequately controlled asthma (GlobeNewswire)
24.05.19	FDA approves Novartis Piqray® - the first and only treatment specifically for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer (GlobeNewswire)
24.05.19	AveXis Announces Innovative Zolgensma® Gene Therapy Access Programs for US Payers and Families (GlobeNewswire)
24.05.19	AveXis receives FDA approval for Zolgensma®, the first and only gene therapy for pediatric patients with spinal muscular atrophy (SMA) (GlobeNewswire)
23.05.19	Novartis highlights company transformation, catalyst-rich pipeline, and strong progress on strategy at Meet Novartis Management investor event (GlobeNewswire)
22.05.19	Novartis phase II data for new inhaled combination treatment (QVM149) demonstrates significant improvements over current standard-of-care inhaled treatment (GlobeNewswire)
16.05.19	Novartis data at ASCO and EHA demonstrate novel approaches to reimagining medicine in cancer and serious blood disorders (GlobeNewswire)
09.05.19	Novartis to acquire Xiidra®, expanding front-of-eye portfolio and strengthening leadership in eye care (GlobeNewswire)
08.05.19	Novartis data at AAN show Mayzent's® positive impact on cognitive processing speed, a core element of cognitive function, in people living with secondary progressive MS (GlobeNewswire)
07.05.19	New AveXis data at AAN showed long-term durability of Zolgensma® in patients with spinal muscular atrophy (SMA) Type 1 (GlobeNewswire)
07.05.19	Novartis presents first-of-its-kind algorithm-based tool to help MS patients and physicians evaluate and discuss early signs of progression to secondary progressive MS (GlobeNewswire)
05.05.19	AveXis presented robust data at AAN demonstrating efficacy of Zolgensma® in broad spectrum of spinal muscular atrophy (SMA) patients (GlobeNewswire)
02.05.19	Novartis to highlight extensive long-term safety and efficacy data of Aimovig® across the spectrum of migraine at AAN (GlobeNewswire)
30.04.19	New data at AAN reinforce Novartis commitment to transforming the lives of people of all ages who live with neurological conditions (GlobeNewswire)
30.04.19	Sandoz enters agreement for proposed trastuzumab biosimilar, currently in Phase III development, to treat selected HER2-positive cancer tumors (GlobeNewswire)
24.04.19	Novartis startet 2019 mit starken Umsätzen und einer zweistelligen Steigerung des operativen Kernergebnisses[1], Einführung von Mayzent sowie Abspaltung von Alcon; Gewinnprognose angehoben (GlobeNewswire)
24.04.19	Novartis starts 2019 with strong sales and double digit core[1] operating income growth, Mayzent launch and Alcon spin-off; profit guidance upgraded (GlobeNewswire)
16.04.19	AveXis data reinforce effectiveness of Zolgensma® in treating spinal muscular atrophy (SMA) Type 1 (GlobeNewswire)
15.04.19	Novartis announces FDA filing acceptance and Priority Review of brolucizumab (RTH258) for patients with wet AMD (GlobeNewswire)
11.04.19	Sandoz drives differentiated portfolio with deal to commercialize new treatment for Opioid-Induced Constipation in key European countries (GlobeNewswire)
09.04.19	Novartis continues transformation into a leading medicines company with completion of the Alcon spin-off (GlobeNewswire)
09.04.19	Alcon Debuts as Independent, Publicly Traded Company (Businesswire)
04.04.19	Novartis updates on the migraine collaboration with Amgen (GlobeNewswire)
03.04.19	Sandoz resubmits biosimilar pegfilgrastim application to US FDA (GlobeNewswire)
02.04.19	Novartis first-in-class Cosentyx® approved in China for psoriasis patients (GlobeNewswire)
01.04.19	AveXis expands world-leading gene therapy manufacturing capacity with purchase of advanced biologics therapy manufacturing campus in Longmont, Colorado (GlobeNewswire)
01.04.19	Novartis adds clinical and preclinical anti-inflammatory programs to portfolio with acquisition of IFM Tre (GlobeNewswire)
27.03.19	Novartis receives FDA approval for Mayzent® (siponimod), the first oral drug to treat secondary progressive MS with active disease (GlobeNewswire)
22.03.19	Novartis plans for Alcon spin-off on April 9, 2019 (GlobeNewswire)
18.03.19	Alcon Announces Acquisition of PowerVision, Inc. (GlobeNewswire)
14.03.19	Novartis joins the Global Chagas Disease Coalition and also announces first multinational, prospective, randomized study in people with chronic Chagas cardiomyopathy (GlobeNewswire)
14.03.19	Novartis announces change in Sandoz leadership (GlobeNewswire)
11.03.19	Three winners of 2019 Sandoz Healthcare Access Challenge (HACk) are announced at SXSW (GlobeNewswire)
05.03.19	Novartis Cosentyx® shows superior improvements in psoriasis patients' quality of life versus Janssen's IL-23 Stelara®* (GlobeNewswire)
04.03.19	Novartis data confirm rapid response and high efficacy of Cosentyx® in psoriasis patients for first time in China (GlobeNewswire)
28.02.19	Die Aktionäre von Novartis heissen an der Generalversammlung alle Anträge des Verwaltungsrates gut (GlobeNewswire)
28.02.19	Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting (GlobeNewswire)
25.02.19	Novartis issues summary financial information for the Alcon eye care business ahead of shareholder vote on proposed spin-off (GlobeNewswire)
25.02.19	Novartis to pursue transformational therapy to reduce risk of cardiovascular disease in people living with elevated levels of inherited lipoprotein(a) (GlobeNewswire)
13.02.19	Novartis receives FDA approval for Egaten® for the treatment of fascioliasis, a neglected tropical disease (GlobeNewswire)
30.01.19	Novartis delivered strong sales growth with core margin expansion, built leading advanced therapy platforms and focused the company in 2018 (GlobeNewswire)
30.01.19	Novartis erzielt 2018 ein kräftiges Umsatzwachstum bei gleichzeitiger Steigerung der Kerngewinnmarge, baut wegweisende Therapie¬plattformen auf und fokussiert das Unternehmen (GlobeNewswire)
08.01.19	Novartis investigational therapy crizanlizumab (SEG101) receives FDA Breakthrough Therapy designation for the prevention of vaso-occlusive crises in sickle cell disease (GlobeNewswire)
07.01.19	Sandoz and Pear Therapeutics Announce US Launch of reSET-OTM to Help Treat Opioid Use Disorder (GlobeNewswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Geberit	545.60	2.17 %	K V
Sika	235.80	1.51 %	K V
CieFinRichemont	127.65	1.43 %	K V
Part Grp Hldg	1’299.50	1.33 %	K V
Holcim	91.86	1.15 %	K V
Roche Hldg G	254.50	-0.66 %	K V
Lonza Grp	525.00	-0.72 %	K V
Sonova Hldg	297.70	-1.03 %	K V
Alcon	77.12	-1.20 %	K V
Swiss Life Hldg	690.40	-4.69 %	K V

mehr

19:37		TELL me! - der Schweizer Trading Podcast: Ausblick 2025: stabil bis positiv - Dividenden Titel: Coca-Cola, Sanofi und Evonik
18:01		Minuszeichen in New York: Dow Jones präsentiert sich mittags leichter
18:01		NASDAQ Composite-Handel aktuell: NASDAQ Composite legt zu
17:58		STOXX-Handel: STOXX 50 zum Handelsende im Aufwind
17:58		SPI-Handel aktuell: SPI steigt zum Ende des Dienstagshandels
17:58		Freundlicher Handel in Frankfurt: TecDAX letztendlich freundlich
17:58		Euro STOXX 50-Handel aktuell: Euro STOXX 50 zum Ende des Dienstagshandels mit Gewinnen